Minerva Neurosciences Inc. Aktie
Minerva Neurosciences (Symbol NERV) (WKN A3DMH5) is a clinical-stage biopharmaceutical company specializing in the development and commercialization of innovative and cutting-edge therapies for central nervous system (CNS) disorders. With a primary focus on neuropsychiatric and neurodegenerative diseases, Minerva Neurosciences aims to address the unmet needs in the treatment of conditions such as schizophrenia, Parkinson's disease, and insomnia. Listed on the stock exchange and driven by a team of experts in neuroscience and biopharmaceutical development, the company strives to improve patients' quality of life and advance the field by translating robust scientific discoveries into groundbreaking therapies that can potentially transform the lives of millions suffering from these debilitating disorders.
Was spricht für und gegen Minerva Neurosciences Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Minerva Neurosciences Inc. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Minerva Neurosciences Inc. | -1,74 % | -5,04 % | -2,59 % | -18,71 % | -61,27 % | -86,18 % | - |
| Ardelyx Inc. | 28,12 % | 34,72 % | 18,97 % | 89,62 % | 39,76 % | 44,25 % | - |
| Evolus Inc | 10,28 % | 12,38 % | -5,60 % | 60,54 % | 30,39 % | 60,54 % | - |
| Salarius Pharmaceuticals Inc. | 11,65 % | 7,98 % | 17,95 % | -67,61 % | -17,12 % | -98,25 % | -99,99 % |
